Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results
about
Using Rich Data on Comorbidities in Case-Control Study Design with Electronic Health Record Data Improves Control of Confounding in the Detection of Adverse Drug ReactionsCausal inference as an emerging statistical approach in neurology: an example for epilepsy in the elderly.Cardiac glycosides and breast cancer risk: A systematic review and meta-analysis of observational studies.Observational data for comparative effectiveness research: an emulation of randomised trials of statins and primary prevention of coronary heart disease.An analytic framework for aligning observational and randomized trial data: Application to postmenopausal hormone therapy and coronary heart disease.Comprehensive evaluations of the adverse effects of drugs: importance of appropriate study selection and data sources.P-values and decision-making: discussion of 'Limitations of empirical calibration of p-values using observational data'.Comparative Effectiveness Research Using Observational Data: Active Comparators to Emulate Target Trials with Inactive Comparators.High-dimensional propensity score adjustment in studies of treatment effects using health care claims dataEvidence of potential bias in a comparison of β blockers and calcium channel blockers in patients with chronic obstructive pulmonary disease and acute coronary syndrome: results of a multinational study.Confounder summary scores when comparing the effects of multiple drug exposuresVariation in the risk of suicide attempts and completed suicides by antidepressant agent in adults: a propensity score-adjusted analysis of 9 years' dataQuantification of missing prescriptions in commercial claims databases: results of a cohort study.Cardiovascular risks in smokers treated with nicotine replacement therapy: a historical cohort study.A basic study design for expedited safety signal evaluation based on electronic healthcare data.Potential and pitfalls of using large administrative claims data to study the safety of osteoporosis therapies.Body characteristics, [corrected] dietary protein and body weight regulation. Reconciling conflicting results from intervention and observational studies?Academic impact of a public electronic health database: bibliometric analysis of studies using the general practice research database.Developments in post-marketing comparative effectiveness researchMedication adherence and use of generic drug therapies.Characteristics of opioid-using pregnant women who accept or refuse participation in a clinical trial: screening results from the MOTHER study.Antihypertensive medication exposure and cardiovascular outcomes in hemodialysis patients.Metformin and low levels of thyroid-stimulating hormone in patients with type 2 diabetes mellitus.Incident user cohorts for assessing medication cost-offsetsCost savings associated with filling a 3-month supply of prescription medicines.The implications of propensity score variable selection strategies in pharmacoepidemiology: an empirical illustration.Oral bisphosphonates and risk of subtrochanteric or diaphyseal femur fractures in a population-based cohortRevisiting the washout period in the incident user study design: why 6-12 months may not be sufficientObservational studies on the risk of cancer associated with tumor necrosis factor inhibitors in rheumatoid arthritis: a review of their methodologies and resultsBias in observational studies of prevalent users: lessons for comparative effectiveness research from a meta-analysis of statins.Controlling Time-Dependent Confounding by Health Status and Frailty: Restriction Versus Statistical Adjustment.Recent prediagnostic aspirin use, lymph node involvement, and 5-year mortality in women with stage I-III breast cancer: a nationwide population-based cohort studyUsing Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available.Confronting "confounding by health system use" in Medicare Part D: comparative effectiveness of propensity score approaches to confounding adjustment.Concomitant use of clopidogrel and statins and risk of major adverse cardiovascular events following coronary stent implantation.Real World Data in Adaptive Biomedical Innovation: A Framework for Generating Evidence Fit for Decision-Making.Control Outcomes and Exposures for Improving Internal Validity of Nonrandomized Studies.Counterpoint: the treatment decision designPoint: incident exposures, prevalent exposures, and causal inference: does limiting studies to persons who are followed from first exposure onward damage epidemiology?Thiazolidinediones and Parkinson Disease: A Cohort Study.
P2860
Q28554566-C210AE5B-35F3-4F4C-9770-6282A984C64CQ30238821-652020B9-838F-4495-B906-D1301747AC67Q30241045-B9CAABAB-08C4-47F1-A190-9CA475F084D8Q30538243-329684B1-7647-4B89-9105-5B1566F083B0Q30696956-25106401-A2BB-45BC-B872-3EC8860E789EQ30840099-33E195A0-5973-4EF1-89FE-E4573E1ED071Q31126637-AA51B75D-6CB3-45BA-834B-FA56DF4DB7D5Q31144980-87109ABA-1B62-4069-A37D-AF40AACFE9E8Q33457966-B015EFE7-04EA-444D-B2B1-523A6A1BBAB1Q33552609-EB66CEED-7E18-46E4-B6E9-1D4CB630BB2EQ33566259-4CF11459-970E-4C29-994E-0AAB48C2AD15Q33571327-50DE0ABC-E77C-4669-BEA2-22EB7A75F30FQ33578224-3C79EE80-2187-4A3C-A785-5CB5FD302A2FQ33627663-1801B33E-9860-4843-9EDC-69DE480C7B8AQ33648230-208CA045-BD88-47DF-96F7-CCB8F89575E0Q33818302-CC77FBE9-E06F-4E38-9B45-2DA386E01FA9Q33843231-E51C4947-097A-4FBB-97B5-8FB9511A3F4AQ33952403-26813B81-C45E-4481-A7AE-9D86501EF487Q34001867-D1F6D165-DF38-454C-8AD5-62AFA7102D8DQ34052798-2213B7F8-755B-4AF7-AC6E-2AF9E9ECAB76Q34078533-13F39BE4-E2FF-48D5-91A4-162CE43F3475Q34244180-AF168D11-E3A7-4E68-BD93-BF061F3BD7ECQ34373289-9E199D32-C51A-439E-9C94-A56E2D8B9B0EQ34553899-93B58959-3836-4C3C-B96D-B6D25BF7DB51Q35012332-85BF530E-4842-4A34-A0B9-ECFF250B346FQ35068828-E9C98D4F-8800-41B8-B89C-8A646AE40E13Q35229899-187E47D1-0A0F-4E5E-BA04-651E88A3A827Q35541348-8BA639C5-16A8-4754-8292-E34C63C1B159Q35621627-BE3DE24F-0E51-4750-9482-588F41668D81Q35734332-FAC6B6F7-AA94-4B83-832F-3C8519FC2B88Q35775682-60E98434-E6E8-4DF8-86FF-73FF3C44AAC8Q35911030-6F0BCCC3-2E54-4254-A719-DF03F7CDB5FFQ35963563-09E9C178-1657-4553-80AF-F83C0A1B3982Q36008497-FB264A51-D092-478C-9096-55A45D456BEEQ36088008-1E29FB59-3DB2-4378-BABD-058B304CA28BQ36132510-D035A5F4-B7CA-4967-8997-2497505767A8Q36144408-D8BC93BF-6D05-4CDE-90D7-D31D3F2526DBQ36251759-BBED0C73-58D9-4386-A830-7811038A9602Q36251771-42B6A38A-59D6-40DA-A412-6CBB134D8697Q36306620-B2E442A1-612E-41D0-BE26-3F8EEBFAEB00
P2860
Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results
description
2007 nî lūn-bûn
@nan
2007 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Increasing levels of restricti ...... with randomized trial results
@ast
Increasing levels of restricti ...... with randomized trial results
@en
Increasing levels of restricti ...... with randomized trial results
@nl
type
label
Increasing levels of restricti ...... with randomized trial results
@ast
Increasing levels of restricti ...... with randomized trial results
@en
Increasing levels of restricti ...... with randomized trial results
@nl
prefLabel
Increasing levels of restricti ...... with randomized trial results
@ast
Increasing levels of restricti ...... with randomized trial results
@en
Increasing levels of restricti ...... with randomized trial results
@nl
P2093
P2860
P50
P1433
P1476
Increasing levels of restricti ...... with randomized trial results
@en
P2093
Amanda R Patrick
Jerry Avorn
Malcolm Maclure
Robert J Glynn
Sebastian Schneeweiss
P2860
P304
P356
10.1097/MLR.0B013E318070C08E
P433
P577
2007-10-01T00:00:00Z